IRVINE, Calif., Nov. 20, 2025 /PRNewswire/ -- PeproMene Bio, Inc., a clinical-stage biotechnology company developing novel therapies for relapsed and refractory (r/r) B-cell malignancies, announced ...
The first heavily pretreated r/r FL patient dosed at City of Hope with PMB-CT01 achieved a CR at one-month post treatment. A Total of 7/7 r/r B-NHL patients including MCL, DLBCL and FL treated with ...
Patients with relapsed/refractory follicular lymphoma will be included in the expansion phase of PeproMene Bio's PMB-102 Phase 1 study evaluating BAFF-R targeting CAR T cells (PMB-CT01) in adult ...
IRVINE, Calif., Nov. 20, 2025 /PRNewswire/ -- PeproMene Bio, Inc., a clinical-stage biotechnology company developing novel therapies for relapsed and refractory (r/r) B-cell malignancies, announced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback